Last reviewed 2026-04-23 · How we verify

abacavir/lamivudine + raltegravir

abacavir/lamivudine + raltegravir is a NRTI/INSTI combination Small molecule drug developed by University of Modena and Reggio Emilia. It is currently in Phase 3 development for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV-1. Also known as: Kivexa, Isentress.

Abacavir/lamivudine is a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) that work by inhibiting the replication of HIV-1, while raltegravir is an integrase strand transfer inhibitor (INSTI) that blocks the integration of viral DNA into the host genome.

Abacavir/lamivudine is a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) that work by inhibiting the replication of HIV-1, while raltegravir is an integrase strand transfer inhibitor (INSTI) that blocks the integration of viral DNA into the host genome. Used for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV-1.

At a glance

Mechanism of action

Abacavir/lamivudine works by inhibiting the reverse transcriptase enzyme, which is essential for the replication of retroviruses like HIV-1. Raltegravir, on the other hand, targets the integrase enzyme, which is responsible for integrating the viral DNA into the host genome. By inhibiting these enzymes, both drugs prevent the replication of HIV-1 and reduce the viral load in the body.

Approved indications

• Treatment of HIV-1 infection in adults and children
• Prevention of mother-to-child transmission of HIV-1

Common side effects

• Nausea
• Diarrhea
• Headache
• Fatigue
• Abdominal pain

Key clinical trials

• Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
• A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
• Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
• Research on the Psychological Status of Patients With HIV-1 Infection
• A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed (PHASE2)
• Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients (PHASE4)
• Observational, Retrospective Analysis in HIV-1 Infected Patients. (ORASWIRAL)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• abacavir/lamivudine + raltegravir CI brief — competitive landscape report
• abacavir/lamivudine + raltegravir updates RSS · CI watch RSS
• University of Modena and Reggio Emilia portfolio CI

Frequently asked questions about abacavir/lamivudine + raltegravir

Related

• Drug class: All NRTI/INSTI combination drugs
• Target: All drugs targeting Reverse transcriptase/Integrase
• Manufacturer: University of Modena and Reggio Emilia — full pipeline
• Therapeutic area: All drugs in Infectious Diseases
• Indication: Drugs for Treatment of HIV-1 infection in adults and children
• Indication: Drugs for Prevention of mother-to-child transmission of HIV-1
• Also known as: Kivexa, Isentress
• Compare: abacavir/lamivudine + raltegravir vs similar drugs
• Pricing: abacavir/lamivudine + raltegravir cost, discount & access